OPsumit USers Registry

Completed

Conditions studied: Pulmonary Arterial Hypertension

In brief

Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.

Key facts

Study ID

NCT02126943

Run by

Actelion

People needed

2686

Starts

2014-04-30

Expected to finish

2020-04-24

Last updated by the study team

2025-03-30

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients newly treated with Opsumit defined as a new user of therapy, initiated ≤ 30 days prior to enrollment visit.
• Signed ICF

You may not qualify if…

• Previous user of Opsumit defined as patient who initiated therapy >30 days prior to enrollment.
• Patients enrolled in any ongoing clinical trials

Where it is running

• Investigator Site — Phoenix, Arizona, United States
• Investigator Site — Phoenix, Arizona, United States
• Investigator Site — Phoenix, Arizona, United States
• Investigator Site — Fullerton, California, United States
• Investigator Site — La Jolla, California, United States
• Investigator Site — Loma Linda, California, United States
• Investigator Site — Los Angeles, California, United States
• Investigator Site — Los Angeles, California, United States
• Investigator Site — Los Angeles, California, United States
• Investigator Site — Moreno Valley, California, United States
• Investigator Site — San Juan Capistrano, California, United States
• Investigator Site — Santa Barbara, California, United States
• Investigator Site — Stanford, California, United States
• Investigator Site — Aurora, Colorado, United States
• Investigator Site — Denver, Colorado, United States
• Investigator Site — Greeley, Colorado, United States
• Investigator Site — Wheat Ridge, Colorado, United States
• Investigator Site — New Haven, Connecticut, United States
• Investigator Site — Newark, Delaware, United States
• Investigator Site — Washington D.C., District of Columbia, United States
• Investigator Site — Brandon, Florida, United States
• Investigator Site — Celebration, Florida, United States
• Investigator Site — Clermont, Florida, United States
• Investigator Site — Fort Lauderdale, Florida, United States
• Investigator Site — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.